Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has released an update on the ongoing ACCENT clinical trial evaluating Amplia’s lead FAK inhibitor, narmafotinib, in combination with gemcitabine and Abraxane® for advanced pancreatic cancer.

Since the last update, the trial has recorded an additional confirmed partial response and one unconfirmed partial response.

Objective Response Rate (ORR) now 33% vs 23% historically with chemotherapy alone

Overall response rate 42% in Phase 2A (n=55)

Mean duration on treatment is 219 days, with 7 patients ≥12 months and 2 patients >18 months

Dr Chris Burns, CEO and Managing Director of Amplia, commented:

“These latest data from the ACCENT trial continue to support our belief that narmafotinib enhances the response to chemotherapy by improving efficacy and durability, whilst being well tolerated in this patient group. Further trial updates will be provided in the coming months, with overall survival (OS) data planned for release in Q1 2026.”

Amplia Therapeutics reports additional responses in ACCENT pancreatic cancer trial